Project Details
Description
A Parallel-group, Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants with Progressive NF2 Mutated Meningiomas
| Status | Active |
|---|---|
| Effective start/end date | 11/23/21 → 12/1/26 |
Funding
- RECURSION PHARMACEUTICALS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.